Medindia

X

Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference

Saturday, May 17, 2008 General News J E 4
Advertisement
VANCOUVER, May 16 /PRNewswire-FirstCall/ - Response Biomedical Corporation(TSX: RBM, OTCBB: RPBIF) today announced that S. Wayne Kay, Chief ExecutiveOfficer, is scheduled to present at the Rodman & Renshaw 5th Annual GlobalHealthcare Conference on Monday May 19th at 10:15 a.m. EDT.

A live web cast of the presentation will be available on the Company's Website atwww.responsebio.com/newsroom_events_calendar_corporate.asp?menu=1&submenu=3and replays will be available for 14 days starting approximately three hoursafter the initial presentation.

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-sitediagnostic tests for use with its RAMP(R) Platform for clinical andenvironmental applications. RAMP(R) represents a new paradigm in diagnosticsthat provides high sensitivity and reliable information in minutes. It isideally suited to both point-of-care testing and laboratory use. The RAMP(R)system consists of a Reader and single-use disposable test cartridges, and hasthe potential to be adapted to more than 250 medical and non-medical testscurrently performed in laboratories. RAMP(R) clinical tests are commerciallyavailable for the early detection of heart attack and congestive heartfailure.

In late 2006, the Company formed a strategic alliance with 3M Company tocommercialize rapid infectious disease tests. In the non-clinical market,RAMP(R) Tests are currently provided for the environmental detection of WestNile Virus, and Biodefense applications including the rapid on-site detectionof anthrax, smallpox, ricin and botulinum toxin. Several other productapplications are under development. Response has achieved CE Marking and itsQuality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.

Response Biomedical is a publicly traded company, listed on the TSX underthe trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol"RPBIF". For further information, please visit the Company's website atwww.responsebio.com.

CONTACT: Response Biomedical Contacts: Bill Wickson, Manager, InvestorRelations, Response Biomedical Corporation, Tel (604) 456-6073, Email:bwickson@responsebio.com; Brian Korb, Vice President, The Trout Group LLC,Tel: (646) 378-2923, Email: bkorb@troutgroup.com

SOURCE Response Biomedical Corp.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
PA Secretary of Health to Discuss Hepatitis Risk F...
S
InterMune to Present at Citigroup Healthcare Confe...